Biopharma funding dropped 20% in 2025 as companies doubled down on big bets: IQVIA Read more →
Innate ends work on NK cell engager in phase 1/2 trial as part of ongoing pipeline refocus Read more →
FDA approves Denali's Hunter syndrome drug, handing rare disease community a win Read more →
